

Growing RD Capacity

Training Research Administrators in Proposal Editing

Melissa W. Li, PhD, CRA, ELS

University of Michigan
Grant Services & Analysis, Office of Research, Medical School

- Research Development
- Research Administration
- Both
- None



Agenda



A Small Difference May Make a Big Impact



Writing mistakes may cost fortune or life!

Rationale

Pre-Workshop

- Support for faculty
- Limited Research Development professionals
- Target audience – Research Administrators
 - Early access
 - Professional development



MEDICAL SCHOOL
UNIVERSITY OF MICHIGAN



MICHR MICHIGAN INSTITUTE FOR
CLINICAL & HEALTH RESEARCH
UNIVERSITY OF MICHIGAN

Internal Pilot

- Content development
 - Collaboration between two offices
 - Meetings
 - Document sharing on cloud
- Pilot workshop
 - Internal
 - Attendees from various units
 - Updates (title, content, style, etc.)

Pre-Workshop



Workshop Detail




Workshop

- Title
- Duration
- Goal
- Content

Topics

- Why grants should be edited
- Editing checklist & tips
- Grant components
- Grant editing example
- Logistics & working with faculty

Workshop



Editing Checklist

Workshop

Topics

Big Picture / Macro Issues	
Organization and logical flow	
	<ul style="list-style-type: none">- Check headings- Check logic of and transitions between sentences, paragraphs, ideas, and sections
Clarity in terminology and reduce jargon and acronyms	
Concise writing by cutting unneeded words, redundancies, and revising long/run-on sentences	
Consistency in the writing and style (e.g., capitalization, hyphenation, font style)	
Visually appealing and easy to skim (e.g., white space)	
Small Details / Micro Issues	
Grammar	
	<ul style="list-style-type: none">- Use active voice- Use first person- Check "a" vs "an" before acronyms/abbreviations- Check for subject/verb agreement- Fix long and run-on sentences
Punctuation	
Spelling (e.g., commonly misused words), typos, and omissions	
Other Issues	
Figures and tables:	
	<ul style="list-style-type: none">- consecutive numbering- ensure text is legible- ensure figure/table is mentioned in text and placed in the appropriate location
Acronyms:	
	<ul style="list-style-type: none">- ensure all acronyms are defined at the beginning of each section- verify correct and consistent use of acronyms- ensure acronym isn't listed if only used once- remove acronyms if many are used and it is difficult to read
Formatting:	
	<ul style="list-style-type: none">- margin- font size & style- consistent spacing between paragraphs and before/after headings- consistent spacing after periods
Page limits	
	<ul style="list-style-type: none">- ensure they are adhered to for all sections and edits do not put them over the limit

← Big Picture

← Small Picture

← Other Issues

Big Picture Editing

Workshop

Topics

- Organization
- Clarity
- Conciseness
- Consistency
- Visual appeal



Small Detail Editing

Workshop

Topics

- Grammar
- Punctuation
- Spelling



Other Editing

Workshop

Topics

- Tables & figures
- Guidelines




Concise Writing

- Cut unnecessary words
 - In order...
 - That
 - Adverbs (-ly)
 - Prepositions
- Remove redundancies
- Revise long sentences

Workshop

Topics



Concise Writing Example

~~In order to assess the patient-provider relationship, we will call up patients who have very high HbA1c levels and ask about their satisfaction, because focusing on these patients will completely ensure that we understand the provider relationship for high-risk patients due to the fact that their HbA1c is so high.~~




To assess the patient-provider relationship, we will call patients who have high HbA1c levels and ask about their satisfaction. This will ensure we understand the provider relationship for high-risk patients.

Formatting & Visual Appeal

Workshop

Topics

- White space is good!
 - Left aligned
 - Spaces between paragraphs
 - Indent paragraphs if no spacing
- Use underline or bold sparingly for emphasis



SPECIFIC AIMS

Cardiovascular disease produces pharmacological inhibition of inflammation-induced disease and blood pressure resistance, suggesting that local inflammation is a key step in the generation of carbohydrate resistance to important cells that regulate blood pressure. The role of inflammation in human heart failure is less clear: the link has been postulated to be causally related, or alternatively secondary

to cell dysfunction or death. The alpha factor beta ($\alpha\beta$) transcription factor plays an important role in the development of carbohydrate resistant genes. *Qrk5* and *Uffe3*, are increased at both the RNA and cell level in fat during poor diets in mice. Further, deletion of the *Uffe3* gene caused mice to become partially resistant to the development of heart failure, carbohydrate resistance, high blood pressure and inflammation during high fat diets. We identified the *Uffe3/Qrk5* activator, Renivol, which had been previously developed for the treatment of ulcers, cancer and high blood pressure. Administering this drug to fat mice produced weight loss and improved blood pressure and carbohydrate sensitivity, reduced inflammation and attenuated heart failure. A target of Renivol in rodents is the fat tissue, where it increases activity of CBRT. Treatment of mice with Renivol from cells and pre-cells, which was responsible for the output and leading to a decrease in serious

In a recent study published in Cardiovascular Medicine, we reported a randomized double blind, placebo-controlled clinical study of 56 patients (47 completed) with heart failure and breast cancer treated for 6 weeks with Renivol or placebo, which revealed a drug-induced statistically significant improvement in blood pressure and hightosamine between placebo and drug-treated patients. In addition, we identified a subset of responders (those displaying a reduction in blood pressure greater than 0.5%), characterized by a distinct transcriptional profile in tissues both at baseline and in response to Renivol treatment, as well as a transient increase in carbohydrates at 2 to 4 weeks. In addition, the blood pressure lowering seen in Renivol-treated patients correlated with higher baseline heart rate levels. These responders also had improved diet sensitivity and reduction in fat. Although we did not have full power to explore the reduction in fat carbohydrates in our proof of concept study, preliminary data suggested that the patients who responded to the drug had higher reduction in carbohydrate fraction as measured by MRI, while fat also correlated to heart rate levels at baseline. These findings have prompted us to explore whether we can induce a sustained blood pressure lowering beyond 6 weeks, and whether we can reliably identify responders according to baseline circulating heart rate levels in a prospective manner. Our objective is to test this here. We propose to explore these questions with the following three specific aims:

- 1) To explore whether Renivol therapy can reliably lead to significant blood pressure lowering at 12 months compared to placebo. We predict that Renivol therapy will result in a clinically meaningful drop ($>0.5\%$) in blood pressure in our drug-treated subjects after 12 months on the study drug.
- 2) To explore whether Renivol therapy can reduce carbohydrates as measured by MRI will be significantly reduced in our drug-treated subjects after 12 months on the study drug.
- 3) To comprehensively assess the molecular signature associated with Renivol therapy. These studies will provide new insights into the molecular basis for the metabolic changes that occur as a result of Renivol therapy in humans.

To address these questions, we will undertake a clinical study in which we will randomize 150 patients with heart failure with inadequate blood pressure control ($>7\%$), carbohydrates (fraction $>5.5\%$) and currently treated only with oral agents, to receive either Renivol 80 mg tid or placebo orally for a period of 12 months. Patients will be stratified for gender, and whether they have a normal or elevated heart rate level at baseline. We will ensure equal numbers of the stratification categories in the randomized patients. Patients will undergo tissue biopsy at baseline and 12 months, and an MRI at baseline and 12 months. Tissue biopsy samples and circulating cells will be studied for gene expression by RNAseq analyses before, during and after drug exposure. We will further obtain biopsies in patients in each category voluntarily at baseline and 12 months to explore gene expression to determine differentially regulated genes by drug exposure as an exploratory endpoint. These studies will provide an opportunity to explore the therapeutic potential of Renivol for heart failure and breast cancer and will allow us to determine if we can truly personalize the treatment of these conditions by evaluating inflammatory markers at baseline, and assessing the molecular effects of Renivol treatment in both tissue and circulating cells. Ultimately, this will have a positive impact on patients.

Save space by moving heading

Underline for emphasis

Indent further and/or include spaces between paragraphs

VS

Make aims stand out

Make separate "impact" paragraph with bolded "Impact" heading

SPECIFIC AIMS. Cardiovascular disease produces a state of chronic, low-grade inflammation in fat. Knockout or pharmacological inhibition of inflammatory pathways in rodents can disrupt the link between genetic- or diet-induced disease and blood pressure resistance, suggesting local inflammation is key in generating carbohydrate resistance to cells that regulate blood pressure. The role of inflammation in human heart failure is less clear: the link may be causally related or secondary to cell dysfunction or death. The alpha factor beta ($\alpha\beta$) transcriptional program is activated in fat, and may play an important role in the development of carbohydrate resistance. We recently reported that the $\alpha\beta$ sensitive genes, *Qrk5* and *Uffe3*, are increased at both the RNA and cell level in fat during poor diets in mice. Further, deletion of the *Uffe3* gene caused mice to become partially resistant to the development of heart failure, carbohydrate resistance, high blood pressure and inflammation during high fat diets. We identified the *Uffe3/Qrk5* activator, Renivol, which had been previously developed for the treatment of ulcers, cancer and high blood pressure. Administering this drug to fat mice produced weight loss and improved blood pressure and carbohydrate sensitivity, reduced inflammation and attenuated heart failure. A target of Renivol in rodents is the fat tissue where it increases energy via increased sensitivity to carbohydrates and increased activity of CBRT. Treating mice with Renivol led to an increase in HF-9 synthesis and secretion from cells and pre-cells, which was responsible for acute lowering of blood pressure via reduced carbohydrate output, leading to a decrease in cancer and cardiovascular outcomes.

In a recent study, we reported a randomized double blind, placebo-controlled clinical study of 56 patients (47 completed) with heart failure and breast cancer treated for 6 weeks with Renivol or placebo, which revealed a drug-induced statistically significant improvement in blood pressure and hightosamine between placebo and drug-treated patients. In addition, we identified a subset of responders (displaying a reduction in blood pressure greater than 0.5%), characterized by a distinct transcriptional profile at baseline and in response to Renivol treatment, as well as a transient increase in carbohydrate levels at 2 to 4 weeks. In addition, the blood pressure lowering seen in Renivol-treated patients correlated with higher baseline heart rate levels. These responders also had improved diet sensitivity and reduction in fat. Although we did not have full power to explore the reduction in fat carbohydrates in our proof of concept study, preliminary data suggested that the patients who responded to the drug had higher reduction in carbohydrate fraction as measured by MRI, while fat also correlated to heart rate levels at baseline. These findings have prompted us to explore whether we can induce a sustained blood pressure lowering beyond 6 weeks, and whether we can reliably identify responders according to baseline circulating heart rate levels in a prospective manner. Our objective is to test this here. We propose to explore these questions with the following three specific aims:

- Aim 1: To explore whether Renivol therapy can reliably lead to significant blood pressure lowering at 12-months compared to placebo.** We predict that Renivol therapy will result in a higher percentage of patients who achieve a clinically meaningful drop in blood pressure at 12 months.
- Aim 2: To explore whether Renivol therapy can reduce carbohydrates at 12 months compared to placebo.** We hypothesize that carbohydrates as measured by MRI will be significantly decreased in our drug-treated subjects after 12 months on the study drug.
- Aim 3: To comprehensively assess the molecular signature associated with Renivol therapy.** These studies will provide new insights into the molecular basis for the metabolic changes that occur as a result of Renivol therapy in humans.

To address these questions, we will undertake a clinical study in which we will randomize 150 patients with heart failure with inadequate blood pressure control ($>7\%$), carbohydrates (fraction $>5.5\%$) and currently treated only with oral agents, to receive either Renivol 80 mg tid or placebo orally for a period of 12 months. Patients will be stratified for gender, and whether they have a normal or elevated heart rate level at baseline. We will ensure equal numbers of the stratification categories in the randomized patients. Patients will undergo tissue biopsy at baseline and 12 months, and an MRI at baseline and 12 months. Tissue biopsy samples and circulating cells will be studied for gene expression by RNAseq analyses before, during and after drug exposure. We will obtain biopsies in patients in each category voluntarily at baseline and 12 months to explore gene expression to determine differentially regulated genes by drug exposure as an exploratory endpoint.

Impact: These studies will provide an opportunity to explore the therapeutic potential of Renivol for heart failure and breast cancer and will allow us to determine if we can truly personalize the treatment of these conditions by evaluating inflammatory markers at baseline, and assessing the molecular effects of Renivol treatment in both tissue and circulating cells. Ultimately, this will have a positive impact on patients.

Left aligned

Not-so-Obvious Spelling Mistakes

- Impotence vs. Importance
- Causality vs. Casualty
- Defiantly vs. Definitely
- Reagents vs. Regents (of the University of Michigan)
- Principle vs. Principal (Investigator)
- Moody vs. Mody (last name)
- Asses vs. Assess (verb)

Don't just trust spell check!

Table Example

Measures	Times
Patient Measures	
Primary outcome, medication adherence, measured 2 ways: patient self-report (past 7 days of behaviors), EMR query (prescription refill examination)	T0, T1, T2, T3

Table X. Study Measures	T0	T1	T2	T3
Patient Measures				
Medication adherence	X	X	X	X

The examples provided in the workshop were extremely helpful.


heart rate	T3
Demographics: age, sex, race, ethnicity, income, education, marital status, employment status	T0
Provider Measures	
Provider demographics: discipline, years in practice, sex, race	T0
Willingness to adopt intervention	T0
Fidelity to intervention	T3
Provider self-efficacy – 11 questions measure provider self-efficacy	T0, T3

Clinical measures (blood pressure, weight, heart rate)	X	X	X	X
Demographics	X			
Provider Measures				
Provider demographics	X			
Willingness to adopt intervention	X			
Fidelity to intervention				X
Provider self-efficacy	X			X

Grant Components

**Workshop
Topics**

- Dissection of NIH instructions
- NIH research grant documents
- Specific Aim page



Audience Engagement

Workshop

- After the checklist walk-through
- Hands-on editing



Workshop

...interactive portion was great

Take-Home Materials

Workshop

- ✓ Specific Aim page with edits
- ✓ Presentation slides
- ✓ Grant editing checklist
- ✓ Editing resources sheet



M | MICH MICHIGAN INSTITUTE FOR CLINICAL & HEALTH RESEARCH
M | MEDICAL SCHOOL UNIVERSITY OF MICHIGAN

GRANT EDITING RESOURCES

Free Resources

- Organization and Logical Flow
 - [Information on topic sentences, paragraphs, and transitions](#)
 - [Transition words](#)
- Clarity
 - [Duke Graduate School Scientific Writing Resource](#)
 - [Acronym List add-on](#) for Word and Google Docs
- Concise Writing

M | MICH MICHIGAN INSTITUTE FOR CLINICAL & HEALTH RESEARCH
M | MEDICAL SCHOOL UNIVERSITY OF MICHIGAN

- <https://writingcenter.unc.edu/figures-and-charts/>
- [Gardner LE1](#), Chung KC, *Graphs, tables, and figures in scientific publications: the good, the bad, and how not to be the latter*, *J Hand Surg Am*. 2012 Mar;37(3):591-6. doi: 10.1016/j.jhsa.2011.12.016
- Guidelines
 - [Tips for reading an NIH FOA](#)
- CV & Bioketch
 - [NIH Bioketch](#): The most frequently used CV format in grant applications
 - [SciENcy](#): Science Experts Network Curriculum Vitae (for bioketches)
 - [ORCID](#): Open Research and Contributor ID; a unique digital identifier for researchers
- Other Free Resources:

Handouts were very helpful and pleasing to read.

- DoD <http://cdmep.army.mil/funding/pa/FY17-ARP-GAL.pdf>, Appendix 4
- Visual Appeal
 - <http://www.writingandspeakingforbusiness.com/blog/hats-making-your-writing-more-visually-appealing>
- Grammar
 - [Grammar tips](#)
 - [Handy grammar guides](#)
 - [How to recognize and change passive voice](#)
 - [Effective writing by Nature Education](#)
 - ["A" vs "an" before acronyms](#)
 - [Information on subject/verb agreement](#)
 - [Information on run-on sentences \(and sentence fragments\)](#)
- Punctuation
 - [Punctuation information](#)
 - [More punctuation resources](#)
- Spelling, Typos, and Omissions
 - [Commonly misspelled words](#)
 - Commonly misused/confused words: [List #1](#); [List #2](#); [List #3](#); [Which vs That](#)
- Tables and Figures
 - <http://abacus.bates.edu/~ganderso/biology/resources/writing/HTWtablefigs.html>
 - <https://dl.sciencesocieties.org/files/publications/style/chapter-05.pdf>

- Software: [Perfect It Pro](#): A program to catch inconsistencies and formatting issues
- Professional Organizations:
 - [American Medical Writers Association](#)
 - [Essential skills workbooks](#)
 - [Macro/micro editing online learning activity](#)
 - [Art of the editor's query webinar](#)
 - [National Organization for Research Development Professionals](#)
- Book: [The Grant Application Writer's Workbook](#)
- Graduate Programs (see more [here](#)):
 - [University of the Sciences](#): MS in Biomedical Writing or certificate
 - [Johns Hopkins University](#): MA in Science Writing or certificate

Survey

Workshop



Date	# of Attendees	Location
August, 2018	32	Medical Campus
September, 2018	19	NCRC*
January 10, 2019	61	Medical Campus
February 7, 2019	43	Medical Campus
June 10, 2019	33	NCRC*
Total	188	

**NCRC: North Campus Research Complex*

Surveys

- Format
 - Paper
 - Online
- 117 surveys
 - 62% response rate



Post-Workshop


Survey Questions



Post-Workshop

- What is your status?
- Years of experience editing scientific/non-scientific portion
- Intend to start offering editing assistance to faculty
- After learning specific editing strategies, confidence in ability to edit
- Interested in attending an advanced proposal editing workshop?
- Comments

Demographics




Post-Workshop


Years of Editing Experience

Post-Workshop

Scientific Portion




Non-Scientific Portion



■ None ■ < 1 year ■ 1-2 years ■ 3-5 years ■ 6-10 years ■ > 10 years

Confidence Building

Post-Workshop



Response ratings:

Strongly agree = 5


Somewhat agree = 4

Neither agree nor disagree = 3

Somewhat disagree = 2


Strongly disagree = 1

Intending to Offer Editing Assistance



Post-Workshop

Attending an Advanced Workshop?



Post-Workshop

Attending an Advanced Workshop?

Post-Workshop



8%

I have done some editing on an 'as needed' basis. The workshop confirmed - for me - my previous approaches to editing proposals and publication drafts. I would be very interested in more advanced editing workshops. Thanks!

- Editing skills are learnable
- The entry-level editing training is effective and helpful
- Many research administrators show interest in proposal editing
- Many have been editing for faculty
- A more advanced workshop is in high demand



- Emphasize the content level in the announcement
- Leave buffer time for “active” participants
- Clarify objectives at the beginning
- Study audience



Potential Next Step: Online Module


Post-Workshop



- Convenient access
- Flexible learning
- Broad impact
- Cost-effectiveness

Potential Next Step: Advanced Workshop

- Proposal components
 - In-depth dissection
 - Rigor & transparency
- Evaluation criteria
- Multiple-project grants
- Logistics



Post-Workshop

Acknowledgement

Pre-workshop

- Meagan Ramsey
- Jill Jividen
- Beth LaPensee
- Brenda Phillips
- Heather Offhaus
- Becky Youmans
- Dave Nassar
- Judy Smith
- Jocelyn Webber




Workshop

- Paula Van Velden
- Morgan Hayward
- Jane Bugden

Post-workshop

- Jane Bugden
- Heather Offhaus



Melissa W. Li, PhD, CRA, ELS
melilimi@umich.edu